MN2 Stock Overview
Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Mentice AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.09 |
| 52 Week High | SEK 4.83 |
| 52 Week Low | SEK 1.75 |
| Beta | 1.02 |
| 1 Month Change | -3.24% |
| 3 Month Change | -9.91% |
| 1 Year Change | -56.46% |
| 3 Year Change | -73.27% |
| 5 Year Change | -62.00% |
| Change since IPO | -66.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| MN2 | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | 2.0% | -0.007% | 2.0% |
| 1Y | -56.5% | -17.8% | 9.6% |
Return vs Industry: MN2 underperformed the German Healthcare Services industry which returned -17.1% over the past year.
Return vs Market: MN2 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| MN2 volatility | |
|---|---|
| MN2 Average Weekly Movement | 9.2% |
| Healthcare Services Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MN2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MN2's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 133 | Frans Venker | www.mentice.com |
Mentice AB (publ) provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas. The company operates through three segments: Systems, Software Licenses and Service. It offers software modules in the areas of acute ischemic stroke intervention, atrial septal defect and patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee intervention, carotid intervention, patient-specific simulation, coronary advanced, essential, and intermediate, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic artery embolization, radiation safety, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, peripheral angiography, and vascular trauma and cardiac rhythm management, as well as supports interventionalists to transition from transfemoral to transradial access.
Mentice AB (publ) Fundamentals Summary
| MN2 fundamental statistics | |
|---|---|
| Market cap | €54.67m |
| Earnings (TTM) | -€2.02m |
| Revenue (TTM) | €23.99m |
2.3x
P/S Ratio-27.0x
P/E RatioIs MN2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MN2 income statement (TTM) | |
|---|---|
| Revenue | SEK 276.06m |
| Cost of Revenue | SEK 32.73m |
| Gross Profit | SEK 243.33m |
| Other Expenses | SEK 266.61m |
| Earnings | -SEK 23.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 88.15% |
| Net Profit Margin | -8.43% |
| Debt/Equity Ratio | 0% |
How did MN2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 06:05 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mentice AB (publ) is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christian Lee | Pareto Securities |
| Rikard Engberg | Penser Access |
| Christian Binder | Redeye |